Granules India Limited Stock Price Today (NSE: GRANULES)

Granules India Limited

835.6037.00 (4.24%)
Market Closed

Fundamental Score

...

Granules India Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Granules India Limited share price today is 835.60, down 4.24% on NSE/BSE as of 16 September 2026. Granules India Limited (GRANULES) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of 20.71K (Cr). The 52-week high for GRANULES share price is 923.65 and the 52-week low is 510.55. At a P/E ratio of 30.88x, GRANULES is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 13.52% and a debt-to-equity ratio of 0.26.

Granules India Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
899.85
Low
816.00
Volume
7.5L
Change
+4.70%

Granules India Limited share price chart: 4.70% return over the past month. 52-week high ₹923.65, 52-week low ₹510.55.

Granules India Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
869.00872.00829.00835.6026.52L (Cr)
917.00923.65872.50872.6021.06L (Cr)
895.95914.85881.25909.3078.51L (Cr)
870.10905.85870.10899.2515.97L (Cr)
899.75901.80878.10884.8014.06L (Cr)
869.00899.85865.00895.3521.12L (Cr)
844.50873.85842.20867.3010.33L (Cr)
853.00863.60838.60848.3011.73L (Cr)
837.50873.50834.00853.8528.29L (Cr)
834.05838.00816.00831.757.88L (Cr)

Granules India Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
828.50923.65816.00835.60+0.86%
827.80883.00814.20828.50+0.08%
817.65910.00804.50824.65+0.86%
780.00817.70736.50813.25+4.26%
699.70804.30690.05773.85+10.60%
629.00730.80602.20699.70+11.24%
569.00640.00547.40620.40+9.03%
552.90606.95537.65582.25+5.31%
600.40627.00531.80570.60-4.96%
562.50624.70540.55598.50+6.40%
565.95578.05529.85556.10-1.74%
522.70587.20522.70565.60+8.21%

Returns & Performance

Poor

Return on Equity (ROE)

13.52%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

18.21%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

20.41%

Average operating profit margin over 5 years

Dividend Yield

0.19%

Annual dividend as % of current share price

Granules India Limited Valuation Check

Good

Price to Earnings (P/E)

30.88x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Shareholding Pattern

Excellent

Promoter Holding

38.82%

% shares held by company founders/management

Good

FII Holding

17.50%

% shares held by foreign institutional investors

Good

DII Holding

16.11%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

63.03%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

22.04%

Revenue growth vs same quarter last year

Average

Revenue Growth (5-Year CAGR)

10.63%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

2.10%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

1.61%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.26x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

7.86x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

851.17 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Granules India Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GRANULES across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Excellent ROCE Performance (18.21%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (20.41%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Robust Profit Growth (63.03%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (22.04%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.26)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (7.86x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 1.56)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Strong Cash Generation (₹851.17 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Strong Institutional Confidence (FII+DII: 33.61%)

Observation: Significant professional investor participation.

Analysis: High institutional holding often signals thorough due diligence.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

High Price-to-Book Ratio (5.45x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Weak Earnings Growth (2.10% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (1.61% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Granules India Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Granules India Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
47.4/100
836
₹20706.17
30.9
Average
13.52%
Average
18.21%
Good
0.3
Excellent
1.61%
Average
10.63%
Good
0.19%
66.4/100
1877
₹450228.65
37.2
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9468
₹250888.75
85.9
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4940
₹167182.32
78.9
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1139
₹113642.26
25.4
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1372
₹110828.94
32.9
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1941
₹104867.93
95.8
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1683
₹96839.82
26.3
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2101
₹96054.51
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1145
₹95565.75
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2294
₹94729.81
46.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Granules India Limited PE Ratio History

Historical price-to-earnings ratio for GRANULES — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202416.72₹592.3035.4x
FY 202321.00₹405.4519.3x
FY 202216.60₹318.8019.2x
FY 202121.95₹336.2015.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Granules India Limited Dividend History

Annual cash dividends paid by GRANULES — dividend yield 0.19%

Financial YearDividends Paid (₹ Cr)
FY 202536.35 Cr
FY 202436.31 Cr
FY 202318.62 Cr
FY 202237.17 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Granules India Limited Quarterly Performance

Latest quarterly metrics for GRANULES — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

22.04%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

63.03%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

10.63%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

1.61%

Compounded annual net profit growth over 5 years

Granules India Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GRANULES — calculated from daily price history

68RSI 14
Neutral — RSI 68

Momentum is balanced — neither overbought nor oversold.

SMA 50
853
▼ Price below SMA 50 — Short-term bearish
SMA 200
692
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
759K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Granules India Limited Financial Statements

Annual income statement, balance sheet and cash flow for Granules India Limited (GRANULES) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Granules India Limited

Loading latest quarterly results...

About GRANULES (Granules India Limited)

Granules India Ltd is a vertically integrated pharmaceutical company headquartered in Hyderabad, India, with a global footprint. It operates across the entire pharmaceutical value ...chain, from active pharmaceutical ingredients (APIs) to finished dosages (FDs), ensuring quality control and supply chain reliability. Granules specializes in manufacturing a diverse portfolio of essential medications, covering pain management, diabetes treatment, cough and cold remedies, and muscle relaxants. The company is renowned for its commitment to innovation, constantly striving to develop novel drug delivery systems and improve existing formulations. With a focus on sustainability and ethical business practices, Granules India Ltd is dedicated to providing affordable and accessible healthcare solutions to patients worldwide. Granules distinguishes itself through its robust manufacturing capabilities and state-of-the-art facilities, enabling the production of high-quality pharmaceutical products at scale. The company's strengths lie in its process chemistry expertise and efficient manufacturing processes, leading to cost competitiveness and timely delivery. Granules is a significant player in both the Indian and international markets, exporting its products to numerous countries across North America, Europe, Latin America, and Asia. Furthermore, the company emphasizes strategic collaborations and partnerships to expand its market reach and product offerings, solidifying its position as a trusted pharmaceutical supplier. This commitment to quality, affordability, and global reach makes Granules a vital contributor to the healthcare landscape. Granules also invests heavily in research and development, consistently seeking to improve its product portfolio and cater to unmet medical needs. Its R&D efforts focus on developing innovative formulations, improving drug efficacy, and reducing side effects. The company maintains a strong regulatory compliance record, adhering to the highest international standards and guidelines. Through its commitment to continuous improvement and innovation, Granules seeks to remain at the forefront of the pharmaceutical industry and contribute to improved patient outcomes globally. With a focus on affordability, innovation, and quality, Granules India Ltd stands as a reliable partner for healthcare providers and patients.

Company Details

Symbol:GRANULES
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Dr. Krishna Prasad Chigurupati B.Sc.
Chairman & MD
Ms. Priyanka Chigurupati
Head of Marketing & Executive Director
Mr. Harsha Chigurupati BBA
Executive Director

GRANULES Share Price: Frequently Asked Questions

What is the current share price of Granules India Limited?

Granules India Limited (GRANULES) trades at ₹835.60 on NSE and BSE. Market cap ₹20.71K (Cr). Educational data only.

What is the P/E ratio of Granules India Limited?

Granules India Limited has a P/E of 30.88x vs industry average 34.89x.

What is the Bull Run score for Granules India Limited?

Granules India Limited has a Bull Run score of 47.4/100 based on 25+ financial parameters.

Does Granules India Limited pay dividends?

Granules India Limited has a dividend yield of 0.19%. Past dividends don't guarantee future payments.

What is the ROE of Granules India Limited?

Granules India Limited has ROE of 13.52%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Granules India Limited?

Granules India Limited has debt-to-equity of 0.26.

Is Granules India Limited a good investment?

Bull Run gives Granules India Limited a score of 47.4/100. This is not investment advice — consult a SEBI-registered advisor.